Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer

Breast Cancer Research

Volumn 12, Issue 6, 2010, Pages

  Ko, Eunkyung ^a   Park, Seong Eun ^a   Cho, Eun Yoon ^a   Kim, Yujin ^a   Hwang, Jung Ah ^b   Lee, Yeon Su ^b   Nam, Seok Jin ^a   Bang, Saik ^a   Park, Joobae ^a   Kim, Duk Hwan ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN M; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; CST6 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SIZE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DNA METHYLATION; FAMILY HISTORY; FEMALE; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PYROSEQUENCING; RETROSPECTIVE STUDY; BREAST TUMOR; CPG ISLAND; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CPG ISLANDS; CYSTATIN M; DNA METHYLATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 78549283515     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2783     Document Type: Article

References (27)

1. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N, Geller BM. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002, 94:1546-1554.
2. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004, 96:906-920. 10.1093/jnci/djh164, 15199110.
3. Sotiropoulou G, Anisowicz A, Sager R. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem 1997, 272:903-910. 10.1074/jbc.272.2.903, 8995380.
4. Zhang J, Shridhar R, Dai Q, Song J, Barlow SC, Yin L, Sloane BF, Miller FR, Meschonat C, Li BD, Abreo F, Keppler D. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res 2004, 64:6957-6964. 10.1158/0008-5472.CAN-04-0819, 15466187.
5. Rivenbark AG, Jones WD, Risher JD, Coleman WB. DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells. Epigenetics 2006, 1:32-44. 10.4161/epi.1.1.2358, 17998816.
6. Schagdarsurengin U, Pfeifer GP, Dammann R. Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene 2007, 26:3089-3094. 10.1038/sj.onc.1210107, 17099723.
7. Song J, Jie C, Polk P, Shridhar R, Clair T, Zhang J, Yin L, Keppler D. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxinv. Biochem Biophys Res Commun 2006, 340:175-182. 10.1016/j.bbrc.2005.11.171, 16356477.
8. Shridhar R, Zhang J, Song J, Booth BA, Kevil CG, Sotiropoulou G, Sloane BF, Keppler D. Cystatin M suppresses the malignant phenotype of human MDA-MB-435 S cells. Oncogene 2004, 23:2206-2215. 10.1038/sj.onc.1207340, 14676833.
9. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, Nephew KP, Huang TH. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004, 64:8184-8192. 10.1158/0008-5472.CAN-04-2045, 15548683.
10. Knowlden JM, Gee JM, Seery LT, Farrow L, Gullick WJ, Ellis IO, Blamey RW, Robertson JF, Nicholson RI. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998, 17:1949-1957. 10.1038/sj.onc.1202107, 9788438.
11. Suo Z, Berner HS, Risberg B, Karlsson MG, Nesland JM. Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 2001, 439:62-69. 10.1007/s004280000392, 11499842.
12. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005, 11:2163-2168. 10.1158/1078-0432.CCR-04-1633, 15788662.
13. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005, 65:1384-1393. 10.1158/0008-5472.CAN-04-3150, 15735025.
14. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Research 2006, 66:7991-7998. 10.1158/0008-5472.CAN-05-4397, 16912174.
15. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001, 159:2249-2256. 1850582, 11733374.
16. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
17. Hewitt SC, Korach KS. Progesterone action and responses in the alpha ERKO mouse. Steroids 2000, 65:551-557. 10.1016/S0039-128X(00)00113-6, 11108859.
18. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002, 277:5209-5218. 10.1074/jbc.M110090200, 11717311.
19. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem 2002, 277:27793-27800. 10.1074/jbc.M202584200, 12021276.
20. Rio C, Buxbaum JD, Peschon JJ, Corfas G. Tumor necrosis factor-a-convertingenzym e is required for cleavage of erbB4/HER4. J Biol Chem 2000, 275:10379-10387. 10.1074/jbc.275.14.10379, 10744726.
21. Ni C-Y, Murphy MP, Golde TE, Carpenter G. γ-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001, 294:2179-2181. 10.1126/science.1065412, 11679632.
22. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L, Kim TW. Presenilin-dependent γ-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 2002, 277:6318-6323. 10.1074/jbc.M110371200, 11741961.
23. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999, 18:2607-2615. 10.1038/sj.onc.1202612, 10353604.
24. Long W, Wagner KU, Lloyd KC, Binart N, Shillingford JM, Hennighausen L, Jones FE. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 2003, 130:5257-5268. 10.1242/dev.00715, 12954715.
25. GenomeNet Database Resources. , http://www.genome.jp
26. Cheung E, Acevedo ML, Cole PA, Kraus WL. Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1. Proc Natl Acad Sci USA 2005, 102:559-564. 10.1073/pnas.0407113102, 545529, 15642950.
27. Schultz JR, Petz LN, Nardulli AM. Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem 2005, 280:347-354.